Alessandra Curioni-Fontecedro

Professor of Oncology

University of Fribourg

Switzerland

Research Interests

Explore related searches

Professors in Switzerland Professors in Immunology Immunology professors in Switzerland

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Alessandra Curioni-Fontecedro is a Professor of Oncology at the University of Fribourg, Switzerland. Her research focuses on pleural mesothelioma, non-small-cell lung cancer, and the clinical implications of SARS-CoV-2 vaccination in cancer patients. She has contributed significantly to the understanding of molecular determinants in oncological treatments and the diagnostic advancements using artificial intelligence in imaging.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (10)

Adrian Sacher

Assistant Professor

University of Toronto

CANADA

View details

C.T. Berger

SWITZERLAND

View details

Ivana Sullivan

SPAIN

View details

Moritz Philipp Günther

SWITZERLAND

View details

Anna Götz

University Hospital of Zurich

SWITZERLAND

View details

Stefanie Hiltbrunner

University of Fribourg

SWITZERLAND

View details

Roland von Känel

University of Zurich

SWITZERLAND

View details

Emanuela Felley‐Bosco

SWITZERLAND

View details

Ronny Ralf Buechel

University Hospital of Zurich

SWITZERLAND

View details

Paul Baas

Professor

NETHERLANDS

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Alessandra Curioni-Fontecedro

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Molecular determinants of sotorasib clinical efficacy in KRAS<sup>G12C</sup>-mutated non-small-cell lung cancer.

Pleural mesothelioma

Multimodality treatment in synchronous oligometastatic NSCLC: Analysis of the ETOP CHESS trial

Clinically Significant Distress and Physical Problems Detected on a Distress Thermometer are Associated With Survival Among Lung Cancer Patients

Characterization of hypermetabolic lymph nodes after SARS-CoV-2 vaccination using PET-CT derived node-RADS, in patients with melanoma

Genomic landscape of pleural and peritoneal mesothelioma tumours

Mutational Landscape and Expression of PD-L1 in Patients with Non-Small Cell Lung Cancer Harboring Genomic Alterations of the MET gene

Diagnostic Value of Fully Automated Artificial Intelligence Powered Coronary Artery Calcium Scoring from 18F-FDG PET/CT

Frequency and temporal evolution of COVID-19 vaccination rate among oncological patients undergoing 18F-FDG-PET

Extended resection for potentially operable patients with stage III non–small cell lung cancer after induction treatment

Collaborators (10)

Adrian Sacher

C.T. Berger

Ivana Sullivan

Moritz Philipp Günther

Anna Götz

Stefanie Hiltbrunner

Roland von Känel

Emanuela Felley‐Bosco

Ronny Ralf Buechel

Paul Baas

Make your next move.

Alessandra Curioni-Fontecedro

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Molecular determinants of sotorasib clinical efficacy in KRAS&lt;sup&gt;G12C&lt;/sup&gt;-mutated non-small-cell lung cancer.

Pleural mesothelioma

Multimodality treatment in synchronous oligometastatic NSCLC: Analysis of the ETOP CHESS trial

Clinically Significant Distress and Physical Problems Detected on a Distress Thermometer are Associated With Survival Among Lung Cancer Patients

Characterization of hypermetabolic lymph nodes after SARS-CoV-2 vaccination using PET-CT derived node-RADS, in patients with melanoma

Genomic landscape of pleural and peritoneal mesothelioma tumours

Mutational Landscape and Expression of PD-L1 in Patients with Non-Small Cell Lung Cancer Harboring Genomic Alterations of the MET gene

Diagnostic Value of Fully Automated Artificial Intelligence Powered Coronary Artery Calcium Scoring from 18F-FDG PET/CT

Frequency and temporal evolution of COVID-19 vaccination rate among oncological patients undergoing 18F-FDG-PET

Extended resection for potentially operable patients with stage III non–small cell lung cancer after induction treatment

Collaborators (10)

Adrian Sacher

C.T. Berger

Ivana Sullivan

Moritz Philipp Günther

Anna Götz

Stefanie Hiltbrunner

Roland von Känel

Emanuela Felley‐Bosco

Ronny Ralf Buechel

Paul Baas

Make your next move.

Molecular determinants of sotorasib clinical efficacy in KRAS<sup>G12C</sup>-mutated non-small-cell lung cancer.